Close search box Search


Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP), the pharmaceutical company developing prescription cannabinoid medicines, is pleased to announce that dosing of all the cohorts of the Phase I, single ascending dose study for OCT461201 has been successfully completed.

No safety or tolerability concerns were exhibited with any dose tested. As a result, OCTP is satisfied that it is safe to proceed to the next stage of clinical development of its lead compound OCT461201.

Read the full story here.

Date posted: 10 October 2023
Article tag: Oxford Cannabinoid Technologies

Related articles

View all news